atai to acquire Beckley Psytech for 105M shares; $30M PIPE priced at $1.84

ATAI Life Sciences N.V.

Entire issued capital of Beckley Psytech acquired for 105,044,902 new ATAI shares; subject to shareholder approval.
Concurrent $30M PIPE: 9,993,341 shares at $1.84 plus pre-funded warrant for 6,311,006 shares at $0.01 exercise price.
Beckley's Phase 2b BPL-003 TRD topline data expected mid-2025; company to rename to atai Beckley N.V.
Founder's family office (Apeiron, 21.1% owner) enters voting and lock-up agreements; supports redomicile to Delaware.
Cosmo Feilding-Mellen and Michael Norris warrantors; break fee up to $10M if shareholder approval not obtained.

item 1.01item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.